BeiGene Reports Second Quarter 2018 Financial Results
read more...
Aug 08, 2018
BeiGene Announces Closing of Its HK$7.08 billion (US$903 million) Hong Kong Initial Public Offering and Global Offering
read more...
Aug 02, 2018
BeiGene Announces Pricing of Its HK$7.08 billion (US$903 million) Hong Kong Initial Public Offering and Global Offering
read more...
Jul 27, 2018
BeiGene Announces Proposed Hong Kong Initial Public Offering and Global Offering
read more...
Jul 24, 2018
BeiGene Initiates Phase 3 Pivotal Trial of Anti-PD-1 Antibody Tislelizumab Combined with Chemotherapy as First-Line Treatment for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer in China
read more...
Jul 24, 2018
BeiGene Initiates Global Phase 3 Trial of PARP Inhibitor Pamiparib in Patients with Advanced Gastric Cancer
read more...
Jul 22, 2018
BeiGene Announces Preliminary Topline Results of Pivotal Trial in China for Anti-PD-1 Antibody Tislelizumab in Hodgkin’s Lymphoma
read more...
Jul 22, 2018
BeiGene Announces Plan to Pursue Accelerated Approval in the U.S. of BTK Inhibitor Zanubrutinib in Waldenström Macroglobulinemia (WM)
read more...
Jul 20, 2018
BeiGene Attends Hearing Before the Listing Committee of the Stock Exchange of Hong Kong Limited
read more...
BeiGene Provides Development Update and Presents Clinical Data on Zanubrutinib at the 23rd Congress of the European Hematology Association
read more...
Jun 06, 2018
BeiGene to Present at the Goldman Sachs 39th Annual Global Healthcare Conference
read more...
Jun 05, 2018
BeiGene to Present at the William Blair 2018 Growth Stock Conference
read more...
Jun 01, 2018
BeiGene to Present Data on Zanubrutinib and Host an Investor Call from the 23rd Congress of the European Hematology Association
read more...
May 17, 2018
BeiGene Initiates Phase 3 Trial of Pamiparib as Maintenance Therapy in Chinese Patients with Ovarian Cancer
read more...
May 15, 2018
BeiGene to Present at the 2018 UBS Global Healthcare Conference
read more...
May 09, 2018
BeiGene Reports First Quarter 2018 Financial Results
read more...
May 04, 2018
BeiGene to Present at the Deutsche Bank 43rd Annual Health Care Conference
read more...
May 01, 2018
BeiGene Appoints Senior Pharmaceutical Executive Dr. Xiaobin Wu as General Manager of China and President of BeiGene, Ltd.
read more...
Apr 16, 2018
BeiGene Presents Clinical Data on Pamiparib in Chinese Patients with Ovarian Cancers or Triple-Negative Breast Cancer at the American Association for Cancer Research Annual Meeting
read more...
